AbbVie Inc (ABBV)
171.73
+3.97
(+2.37%)
USD |
NYSE |
Nov 21, 16:00
171.97
+0.24
(+0.14%)
After-Hours: 20:00
AbbVie Enterprise Value: 367.30B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 367.30B |
| November 20, 2024 | 360.29B |
| November 19, 2024 | 358.19B |
| November 18, 2024 | 357.67B |
| November 15, 2024 | 355.39B |
| November 14, 2024 | 363.59B |
| November 13, 2024 | 364.87B |
| November 12, 2024 | 366.17B |
| November 11, 2024 | 372.08B |
| November 08, 2024 | 416.38B |
| November 07, 2024 | 418.16B |
| November 06, 2024 | 419.38B |
| November 05, 2024 | 420.23B |
| November 04, 2024 | 418.09B |
| November 01, 2024 | 423.53B |
| October 31, 2024 | 424.10B |
| October 30, 2024 | 419.91B |
| October 29, 2024 | 398.62B |
| October 28, 2024 | 399.02B |
| October 25, 2024 | 395.78B |
| October 24, 2024 | 398.96B |
| October 23, 2024 | 395.84B |
| October 22, 2024 | 397.39B |
| October 21, 2024 | 393.47B |
| October 18, 2024 | 397.57B |
| Date | Value |
|---|---|
| October 17, 2024 | 397.06B |
| October 16, 2024 | 400.40B |
| October 15, 2024 | 402.87B |
| October 14, 2024 | 409.57B |
| October 11, 2024 | 406.99B |
| October 10, 2024 | 407.27B |
| October 09, 2024 | 407.98B |
| October 08, 2024 | 404.90B |
| October 07, 2024 | 405.96B |
| October 04, 2024 | 407.16B |
| October 03, 2024 | 409.21B |
| October 02, 2024 | 411.63B |
| October 01, 2024 | 411.88B |
| September 30, 2024 | 412.80B |
| September 27, 2024 | 401.59B |
| September 26, 2024 | 396.48B |
| September 25, 2024 | 395.35B |
| September 24, 2024 | 399.33B |
| September 23, 2024 | 399.89B |
| September 20, 2024 | 399.25B |
| September 19, 2024 | 399.52B |
| September 18, 2024 | 398.32B |
| September 17, 2024 | 399.22B |
| September 16, 2024 | 403.25B |
| September 13, 2024 | 400.56B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.05B
Minimum
Mar 23 2020
424.10B
Maximum
Oct 31 2024
293.25B
Average
307.07B
Median
Aug 05 2022
Enterprise Value Benchmarks
| Amgen Inc | 207.22B |
| Johnson & Johnson | 389.84B |
| Eli Lilly and Co | 739.59B |
| Merck & Co Inc | 276.21B |
| Pfizer Inc | 199.35B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.561B |
| Revenue (Quarterly) | 14.46B |
| Total Expenses (Quarterly) | 10.55B |
| EPS Diluted (Quarterly) | 0.88 |
| Gross Profit Margin (Quarterly) | 70.87% |
| Profit Margin (Quarterly) | 10.80% |
| Earnings Yield | 1.68% |
| Operating Earnings Yield | 4.77% |
| Normalized Earnings Yield | 1.837 |